Search results
Showing 136 to 150 of 169 results for asthma
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)
This evidence summary has been updated and replaced by NICE guideline NG80.
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)
This evidence summary has been updated and replaced by NICE guideline NG80.
Evidence-based recommendations on artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)
This evidence summary has been updated and replaced by NICE guideline NG80.
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
In development Reference number: GID-TA11277 Expected publication date: TBC
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)
This guidance has been updated and replaced by NICE technology appraisal guidance 278.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC